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PREDICTION OF ACCRUAL CLOSURE DATE IN MULTI-CENTER
CLINICAL TRIALS WITH POISSON PROCESS MODELS
Yuan Kong, PhD
University of Pittsburgh, 2009
Objective: To develop a systematic statistical approach to estimate accrual closure date
in large scale multi-center clinical trials or large public health studies. It is relevant to the
research in public health.
Background: In a typical multi-center cancer clinical trial or large public health study,
sample size is predetermined to achieve desired power and study participants are enrolled
from hundreds of satellite sites. As the accrual is closing to the target size, the coordinating
data center needs to project an accrual closure date based on observed accrual pattern and
notify participating sites several weeks in advance. In the past, projections were simply based
on some crude assessment and conservative measures were incorporated in order to achieve
the target accrual size. The resulted excessive accrual size usually leads to unnecessary
budget increase considering that the coordinating center needs to pay thousands of dollars
for each accrued participant.
Method: For multi-center clinical trials, there is very small probability for a site to
accrue a patient during a short period and mostly the accrual from different sites is mostly
independent from each other. Therefore, the overall accrual could be modeled by a Poisson
process. Based on accrual data collected up to a time point, a Poisson process-based method
was used to analyze the past accrual pattern. Combining with assumption on the future
accruing pattern, two methods were proposed here to predict the accrual closure date. The
estimates and their confidence intervals were used to guide clinical practice. . The proposed
methods were illustrated through analysis of accrual data from NSABP trials B-38 and C-08.
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1.0 INTRODUCTION
A clinical trial is a prospective study that compares the effects and other aspects of one
or more treatments or interventions against a control in human beings. It has become an
integral component of development of new drugs and interventions in the pharmaceutical
industry and health science studies. Study participants are usually enrolled and followed
up for a pre-determined period. The effects of designated interventions on the health of
participants are then recorded and studied. In general, there are four types of clinical trials.
Phase I clinical trials are used to determine the maximal tolerated dose. Phase II trials are
used to evaluate the effects and side effects of the new interventions. Phase III trials are
designed to compare effects and safety of the new interventions against a control. Phase IV
trials sometimes are conducted to follow up new interventions that are shown effective in
phase III trials. Among them, phase III trials are usually the most visible ones because they
are large and costly, and their results will determine the fate of new interventions that have
been shown promising in earlier stages.
The spending on clinical trials is enormous and ever increasing, although patient care
costs for clinical trials are not appreciably higher than costs for patients not enrolled in
trials. Compared to phase I and II trials, phase III trials are relatively more expensive. The
average cost of a phase III clinical trial could potentially exceed $20,000 per patient. There
could be many reasons for the higher spending on the clinical trials. Some are necessary
costs which are hard to avoid, such as costs on patient registration, treatment, subsequent
health management, and data collection. However, some costs, such as cost due to extra
enrollment beyond the target sample size, may be lessened. In a multi-center phase III
trial, the sample size is pre-determined in order to achieve sufficient power for its primary
hypothesis. Participants are often recruited from hundreds of study centers such as hospitals,
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community clinics and cancer institutes over time. Because of the complexity of recruiting
process, it is almost impossible for the coordinating center, especially of cancer clinical trials,
to determine a cut-off date on accrual and eventually reach the target sample size exactly.
It has been the usual practice to choose a cut-off date so that reaching the target sample
size can be ”guaranteed” though this often leads to extra and sometimes excessive accruals.
Extra accruals to a certain degree are helpful because they would fill in for participants who
later on withdraw consent or lose to follow up. However, excessively extra accrual would
increase unnecessary financial burden on the coordinating centers and their sponsors.
Based on some trials we observed at National Surgical Adjuvant Breast and Bowel Project
(NSABP), one of the Cooperative Groups of National Cancer Institute, additional patients
were accrued beyond the target sample sizes. The primary interest of this paper is to provide
a systematic and statistical method to determine the closure date so that we could reach
the target sample size at the end of the closure day without recruiting too many additional
patients although sometimes accruing several additional patients will be helpful to guarantee
the enough sample size. There could be ineligible patients who can not pass the screening,
especially in cancer clinical trials. Therefore having a few more patients would help to
maintain sufficient power. But investigators usually wish to limit the additional accrual to
a certain extend.
The Clinical Trials Cooperative Groups of the National Cancer Institute consist of re-
searchers at affiliated institutions to jointly design and carry out multi-center cancer treat-
ment and prevention clinical trials. These seventeen groups accrue approximately 20,000
new patients at an annual basis. The majority of those clinical trials are phase III trials,
and often thousands of patients are required in a single trial. Usually, the sample sizes are
determined prior to the initiation of trials in order to achieve sufficient power for the primary
hypotheses. The NSABP study B-38 was designed as a phase III clinical trial to compare the
treatment efficacy of three adjuvant chemotherapy regimens for node-positive breast cancer
patients. A target sample size of 4,800 was required to achieve sufficient power for the pri-
mary hypothesis. Another NSABP randomized phase III trial, C-08, was to compare two
adjuvant regimens on colon cancer patients, 2632 was the target sample size.
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In practice, patients are accrued from hundreds of participating institutions or sites over
time. As the accrual is approaching the target sample size, the coordinating data center is
required to project an accrual closure date, based on the observed accrual pattern after the
first patient entering the trial, and notify participating members of this closure date several
weeks in advance. The reason to make the prediction several weeks in advance is because
patient accrual is a complicated process, in which the participating centers need days or
even weeks to evaluate the eligibility of potential participants and acquire their consent to
the study. After the coordinate center finds out the target sample size is reached, it cannot
request the participating centers to discontinue patient enrollment abruptly because some
potential participants have already entered the accrual process though not completed. Such
estimated closure dates are usually based on a simple assessment of the observed accrual
pattern, such as averaging accrual for the past few months. Then the length of further
accrual period is determined by the required amount of further accrual to reach the target
sample size and the estimated accrual rate. Conservative measures, such as adding a few
more days of accrual, are also incorporated in order to reach the target accrual and guarantee
sufficient power for the primary analysis. In B-38, projection of the accrual closure date
occurred about 6 weeks before the closure date and 4,894 patients were actually accrued at
the end of the closure date. In C-08, projection of the accrual closure date also occurred
about 6 weeks before the closure date and 2710 patients were actually accrued at the end of
the closure date. Some of the extra accruals in the B-38 study and C-08 study are helpful
because dozens of participants withdrew consent and another few were deemed ineligible
afterwards.
In many occasions, such overflow of accrual in large multi-institutional clinical trials
usually leads to unnecessary budget increase, considering that the cost for treatment and
management on an average cancer patient takes tens of thousands of dollars. If there are
about 2.5% more patients than necessary, each year this will add about tens of million
of dollars in cost solely for managing patients who participate trials of these Cooperative
Groups. In order to obtain a more precise prediction of the closure date, we pursue a
systematic and statistical approach to predict closure date in a multi-center clinical trial. At
first a Poisson process model was used to model the observed accrual pattern for a specific
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trial up to the time when the coordinating data center is required to project an accrual
closure date. Then functions, such as mean and quantiles, of a future date when the accrual
reaches the target sample size would be estimated based on obtained inference results on the
observed accrual pattern and assumptions on the future accrual pattern. Related issues such
as model diagnostics and sensitivity analyses, under alternative assumptions of the future
accrual pattern, were investigated here. Extension to under more complex settings would
be considered. The proposed method would supply a simple, rigorous and robust tool for
efficient accrual in multi-center clinical trials.
1.1 THE MOTIVATING EXAMPLE: NSABP B-38 TRIAL
In 2004, a phase III trial B-38 was designed by NSABP to compare the treatment efficacy
of three adjuvant chemotherapy regimens for node-positive breast cancer patients. The
accrual size of 4,800 was pre-determined in order to achieve sufficient power for the primary
hypothesis that the investigative arm, dose-dense doxorubicin and cyclophosphamide (AC)
followed by paclitaxel plus gemcitabine, improved the disease-free survival over the other
two arms, docetaxel plus AC, and dose-dense AC followed by paclitaxel alone, respectively.
Patients were accrued from hundreds of participating institutions or sites over time. The
protocol was opened on October 1, 2004, and the first patient entered this trial on November
3, 2004. As the cumulative accrual was closing to the target sample size, a total of 4465
patients were accrued by March 20, 2007. The coordinating data center was required to
project an accrual closure date for this trial based on the accrual pattern before March 20th,
2007 and send it to participating sites several weeks in advance. At that time, May 3 of 2007
was determined as the closure date. This prediction was based on the average daily accrual
during the 3-month period before March 20, 2007 and three more days were added in order
to make sure that the target sample size would be reached. The speculation of future accrual
rate was crude. Eventually, 4894 patients were randomized in this trial at the end and the
final accrual was 94 over the target sample size.
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Figure 1: Overall Daily Accrual For NSABP Trial B-38.
Figure 1 shows the daily accrual in B-38 over time. Several interesting phenomena
were observed. First, during the first 4 or 5 months, the accrual rate was increasing steadily,
reflecting that it took time for the participating institutions to fulfill regulatory requirements
and start recruiting patients for this trial. Secondly, the accrual pattern became relatively
stable after March of 2005. At the last, during the last few days of the accrual period prior
to the designated closure date, the daily accrual increased to about twice of the average
daily accrual during the middle of the accrual period. Information from this study supplied
an excellent opportunity for us to study the accrual patterns for typical cancer clinical trials
and prediction of the trial closure dates.
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2.0 EXISTING APPROACHES ON THE PREDICTION OF TRIAL
CLOSURE
In a multi-center clinical trial, a target sample size is pre-determined in order to achieve
reasonable power for the primary hypothesis. Whether the target accrual size can be reached
in a timely fashion often has great impact on the time frame of the definitive analysis. A
fast accrual will lead to an early closure date and subsequent early dissemination of the
study results to the public. Usually at the design stage of a trial, an accrual pattern is
anticipated based on accrual information from past trials on similar study population. Then
the investigators have an idea about how long the accrual will take and when the definitive
analysis will be expected. In clinical practice, the first patient may not be entered until days
or weeks after the initiation of the trial because it takes time for the participating institutions
to prepare themselves for regulatory requirements and put patients on the trial. With more
and more institutions gear up for the trial, the accrual rate starts to increase steadily until
reaching a stable level. If this stable accrual rate is higher than the anticipated rate, the
accrual can be completed earlier than expected and the primary analysis can be carried out
earlier. Otherwise, the primary analysis may be delayed because of slower accrual. In cases
when the actual accrual rate is much slower than anticipated, interventions such as soliciting
aggressive efforts from participating centers are necessary. Sometimes a trial has to be closed
when possible interventions to speed up accrual have been exhausted but the accrual rate is
still far below the anticipated level.
If the accrual rate is satisfactory and the cumulative accrual is approaching the target
sample size, the coordinating center usually needs to predict a date when the accrual will
reach the target sample size and notify the participating institutions in advance. The member
institutions can keep recruiting patients until the end of this disseminated closure date. If
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the eventual accrual size is a lot less than the target sample size, then the study may be
considerably under-powered than planned. If the eventual accrual size is much larger than
the target sample size, then unnecessary expenditure on accrual incurs. Therefore it is
important for the coordinating center to appropriately determine the closure date when the
target sample size will be reached without incurring unnecessarily extra accruals.
Current practice in the prediction of the closure date is mostly carried out as following:
first calculate the number of accruals that is needed to reach the target sample size, then
divide this number by the average daily or weekly accrual rate during past few months. This
method will supply a crude estimator of time period for further accrual with assuming that
the future accrual will follow the same rate as observed in the past few months. Sometimes
a few extra days or weeks are added as a conservative and precautionary measure. This
approach is simple and reasonable but is often rough and inadequate. During the past
decade, Senn (1998) [15], Anisimov and Fedorow (2007) [3] and Gajewski et al. (2008) [9]
provided some systematic procedures to predict the closure date based on Poisson process
models for accrual patterns.
2.1 A POISSON PROCESS-BASED FRAMEWORK
In a typical multi-center phase III trial carried out by NSABP, hundreds of participating
institutions recruited hundreds or thousands of patients during 2 to 4 years. Consequently,
the chance for a single institution to recruit one patient during a short period such as a
day would be small, let alone the chance to recruit more than one patient. Therefore, the
total accrual from those institutions during a short period approximately follows a Poisson
distribution (Taylor & Karlin, 1998 [16]). In general the patient accruals during disjoint time
intervals are independent from each other. These properties lead to an observation that the
accrual process approximately follows a Poisson process (Taylor & Karlin, 1998 [16]).
Consider a multi-institutional trial, the daily accrual from all participating institutions
is denoted by {X(t), t = 1, 2, . . .}. Assume that patient accrual follows a Poisson process
with accrual rates {λ(t), t = 1, 2, . . .}, where t indicates the time from initiation of the trial
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or some specific date such as the date when the first patient is recruited. The cumulative
accrual up to time t would be:
N(t) =
t∑
s=1
X(s).
Senn (1998) considered modeling the accrual process as a homogeneous Poisson process
with constant rate λ. Denote WN(t)+1 as the sojourn time from the arrival of the N(t)th
patient to the next accrual. Then this sojourn time follows an exponential distribution with
mean 1/λ and its density is
f(w) = λe−λw.
For the prediction of accrual time, assume that N is the target sample size and λ is
known, then the required time to recruit N − N(t) after time T = t, or the waiting time
till the target sample size, follows a gamma distribution with scale 1/λ and shape N −N(t)
(Taylor & Karlin, 1998 [16]; Senn, 1998 [15]).
Compared to some common methods for predicting the closure date in practice, such as
those based on averaging accrual for the past few months, the method which Senn (1998) [15]
proposed was based on a simple and proper statistical model for general practice. Although
the model is rather simple without considering some complicated scenarios, this framework
would supply a straightforward and useful starting point before more extensive exploration.
In practice, the accrual rate, λ, is often unknown and can be estimated based on prior
accrual data {X(s), s = 1, 2, . . . , t.}. However, Senn (1998) [15] did not give a clear guidance
on how to estimate λ. It could be estimated based on some historical clinical trials which
share some similarity at patient characteristics, treatment regimen and etc. The estimation
could base on partial accrual pattern from the same clinical trial if we only need to predict
the closure date after certain amount of patients accrued. Moreover, Senn (1998) [15] did
not consider the possibility of the fluctuation of the accrual rate over time, like what we
observed in the motivation example - NSABP trial B-38. The accrual rate increased at
the first 4-5 months, and then it became relatively stable for a while until the last 5 days
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when the accrual rate nearly doubled. This whole accrual process showed more variability
than a homogeneous Poisson process. Furthermore, Senn (1998) [15] did not discuss how
the variability of the estimated λ would affect the estimated mean time required for further
accrual.
2.2 A BAYESIAN METHOD UNDER THE POISSON PROCESS-BASED
FRAMEWORK
Gajewski et al. (2008) [9] proposed a Bayesian method to predict accrual closure date
under Senn (1998) [15]’s Poisson process framework. Denotes ti as the times when each
new study participant enters the trial and assume that the study starts at time t0 = 0.
Denote wi = ti− ti−1 as the waiting times from accruing the (i−1)th participant to accruing
the ith participant. They assumed that the underlying Poisson process is homogeneous
and consequently the waiting time, wi, follows an exponential distribution with mean 1/λ.
Gajewski et al. (2008) [9] believed that such an assumption conformed to what they observed
in clinical practice and also most clinical trials have prior information on the parameter 1/λ.
In their Bayesian approach, the inverse gamma distribution was selected as the prior for
λ with parameters (α, β). It is the conjugate prior. Gajewski et al. (2008) [9] proposed to
determine the values of parameters for the prior distribution, or hyper-parameters, based
on historical clinical data. If the prior parameters were identified based on some historical
clinical trials from a similar population, a possible weight for the prior parameters was also
discussed given the sample size of the historical clinical trials. Basically, if the historical trial
has less target sample size than the current trial, then the prior can be weighted equal to
the size of the previous sample size. Otherwise, the prior will be weighted less so it will not
overwhelm the posterior distribution with data that are not directly related to the current
trial.
Given the accrual data up to time t, D(t) = {X(s), s = 1, 2, . . . , t.}, the interest is
to estimate the additional waiting time for accruing the remaining N − N(t) patients. If
the waiting time wi follows an exponential distribution, the predictive distribution of an
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unobserved WN(t)+1 has a closed form. For more general cases, Gajewski et al. (2008) [9]
derived its posterior distribution p(λ | D(t)). In order to predict the length of further accrual
time for reaching the target sample size, Gajewski et al. (2008) [9] proposed the following
procedure to generate a random sample of time needed to reach the target sample size N :
(i) Draw λ from its posterior distribution p(λ | D(t)).
(ii) Generate the waiting times WN(t)+1,WN(t)+2, . . ., and WN from exponential distributions
with the drawn λ as parameter.
(iii) Sum up the simulated waiting times.
With repeating this procedure for numerous times, a distribution of the length of further
accrual time could be presented for decision making. As a matter of fact, this procedure can
be simplified by simulating the time to reaching the target sample size directly by a gamma
distribution instead of a sum of numerous waiting times. It is because that essentially they
assumed that the accrual followed a homogeneous Poisson process. Based on the theory of
Poisson process, the required time to recruit the remaining patients N−N(t), or the waiting
time WN(t)+1, follows a gamma distribution.
Gajewski et al. (2008) [9] also compared three different priors, such as only the infor-
mation at the beginning of the study based on investigators’ opinion, non-informative prior
without any background information about the accrual pattern, and informative prior based
on partially observed data. Based on the examples presented in the paper, Gajewski et al.
(2008) [9] concluded that the greatest degree of uncertainty occurs with the non-informative
prior.
Compare to some prediction of accrual rates made on ad hoc basis, this approach by
Gajewski et al. (2008) [9] is a quantitative and rigorous. However, they also assumed that
the accrual followed a homogeneous Poisson process. As we discussed, most of the trials show
more variability than a homogeneous Poisson process. Although this procedure is straight-
forward and easy to implement, it over-simplified the accrual process. Also, the inference is
a little complex and ambiguous in terms of computation and choice of the prior distribution
of λ. Like all other models based on Bayesian method, selecting the appropriate prior distri-
bution is sensitive and can be very subjective. In this paper, identifying the parameters for
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the prior distribution is also very subjective since it is based on the investigator’s personal
knowledge and experience. Gajewski et al. (2008) [9] argued that a research would have
at least some ideas about the projected accrual rate at the designing stage and their model
also account for some uncertainty of the accrual rate since they asked questions about their
confidence about the overall accrual process when preparing for the prior parameters, instead
of their opinions about the accrual rates.
2.3 A POISSON-GAMMA MODEL
Anisimov and Fedorov (2007) [3] considered a more complex Poisson-gamma model. They
argued that in real trials, the accrual rates varied across centers and the starting times
for centers were different. The resulted accrual process would be more complicated than a
homogeneous Poisson process. They proposed to model this variability by assuming that
the accrual rates from participating centers follow a gamma distribution and patient arrival
within each center follows a homogeneous Poisson process. It was called a Poisson-gamma
model by Anisimov and Fedorov (2007) [3], or a compound Poisson process in the literature.
Denote ni(t) as the number of accruals at a participating institution or center i up to
time t and n(t) =
∑m
i=1 ni(t) as the total number of patients accrued up to time t from all
m centers. Furthermore, it was assumed that patients arrival at each center i followed a
homogeneous Poisson process with a site-specific rate λi. These rates were unknown and
assumed to follow a gamma distribution, Ga(α, β). Therefore the overall accrual up to time
t is a Poisson process with the following rate:
Λ(t) =
m∑
i=1
λi1{t ≥ ui},
where ui is the time when accrual at institution i was initiated; 1{t ≥ ui} = 1 when t ≥ ui,
1{t ≥ ui} = 0 otherwise.
The overall accrual would be a heterogeneous Poisson process with instantaneous rate
Λ(t) which is a random variable and each newly initiated center would add an additional
rate λi after ui. However, ui, the time when accrual at institution i is initiated is rarely
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available. If assume that all centers are initiated simultaneously at the same time t0 and
the institution-specific rate λis are known, the overall accrual would become a homogeneous
Poisson process with constant rate Λ(t) ≡ Λ =∑mi=1 λi.
Given observed accrual data up to time t, {xi(s), i = 1, 2, . . . ,m; s = 1, 2, . . . , t}, Anisi-
mov and Fedorov (2007) [3] considered the prediction of the remaining accrual time under
the assumption that all institutions would continue recruit without interruption and no more
institutions would join after time t. Hence the future accrual would follow a homogeneous
Poisson process with rate Λ =
∑m
i=1 λi. Based on the theory of homogeneous Poisson pro-
cesses, the remaining recruitment time to reach the target sample size N follows a gamma
distribution, Ga(N − n(t), 1/Λ) when Λ is known.
With assuming that {λi}s are random and follow a gamma distribution Ga(α, β), the the
future accrual process then follows a Poisson process with a random rate Λ ∼ Ga(mα, β).
After estimating the hyper-parameters using either maximum likelihood or method of mo-
ments, the distribution of Λ is known and so are the distribution of needed further accrual
time, which follows Ga(N − n(t), 1/Λ).
Anisimov and Fedorov (2007) [3] focused on the occupancy problem in multi-center
clinical trials that not all participating centers contribute patients during any given period.
Much of their discussion on estimation and prediction of future closure date centered on that
concept.
The model by Anisimov and Fedorov (2007) [3] assume patients arrive at different centers
according to Poisson process and the rates are a sample from a gamma distribution. They
believe that their model reflects the natural variation in recruitment rates observed in practice
and it was applied in several of completed trials. It can serve as a basic recruitment model.
However, it can not model the complicated scenarios in the process of patient accrual like
the high accrual rate at the end of the trial or the fluctuation of the accrual pattern over
time. The method of predicting of remaining recruitment time is rather complex and is hard
to apply in real life.
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3.0 A FLEXIBLE POISSON PROCESS MODEL FOR PATIENT ACCRUAL
IN MULTI-CENTER TRIALS
3.1 INTRODUCTION
In a typical large multi-center phase III cancer clinical trial, usually thousands of patients are
required. Patients are recruited from hundreds of participating sites from various medical
institutions or hospitals. During a work day, there is a small chance for a single institution to
put a patient on the trial. Patient accrual during a certain time period is mostly independent
from the accrual during another disjoint time period. The accruals from different sites are
usually independent from each other as well. Therefore Poisson processes supply a natural
tool to model the patient accrual for a phase III trial (Kingman, 1993 [13]; Taylor & Karlin,
1998 [16]; Senn, 1998 [15]).
After a multi-center trial is initiated, it usually takes several weeks for institutions to
prepare themselves before the start of recruiting patients. They need to get IRB approval
first before accrual and some sites may need to hire staff to operate the trial. Such gap is
also differential among institutions, for example, teaching hospitals that are affiliated with
research universities may have better trained doctors and staff members and subsequently
shorter gap for gear-up than the community-based medical clinics. During this initiation
period, the daily accrual rates increase slowly until all sites are ready to accrue patients.
Therefore the homogeneous Poisson process model (Senn, 1998 [15]; Gajewski et al., 2008
[9]) cannot be applied under this circumstance. There is more variability than a homogeneous
Poisson process, which assumes the accrual rates are constant from the beginning of the trial
to the closure day.
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Furthermore, the time of initiation for each participating institutions may not be recorded
at the data coordinating center and this will make the application of the approach by Anisi-
mov and Fedorov (2007) [3] rather difficult. They considered a homogenous Poisson process
with a random accrual rates for each participate center, as all centers did not initiate si-
multaneously. Often times, the time when each institution is ready to accrue might not be
available in the database since it is usually less important in the process of patient accrual.
After a closure date is predicted, often we can observe a dramatic increment in daily
accrual during the last few days before the designated closure date. This phenomenon
was observed in many NSABP trials, including B-38 and C-08, and it reflected that the
participating institutions had tried their best to put their patients on the trial before the
deadline because they believed that their patients would be benefited. All existing methods
are not able to handle prediction for trials with this aspect.
In practice, when a closure date is predicted, the participating institutions are allowed
to recruit by the end of that day and the data coordinating center cannot put a stop solely
based on the cumulative accrual. Gajewski et al.(2008) [9], Anisimov and Fedorov (2007)
[3] both tried to supply an estimator of the mean remaining accrual time or an empirical
distribution of the remaining accrual time, provided that the exact arrival times for existing
participants are known. However, in clinical practice, the arrival dates, rather than the exact
arrival times, for existing participants are recorded. The coordinating centers also provide
a predicted date, rather than a time point, as the trial closure date. Although it is a minor
problem and those methods may supply a valid estimator by using the ceiling of the original
estimator, its operating characteristic is not clear. Moreover, all of the exciting methods did
not discuss on the model diagnostics of the required assumptions such as Poisson process
and homogeneity of the accrual rate.
In this chapter, we present a flexible Poisson process-based model for describing patient
accrual, two methods for prediction of the trial closure date, model diagnostics and some
sensitivity analyses. These methods are illustrated through analysis of the accrual data from
the NSABP B-38 and C-08 trials in Chapter 4.
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3.2 A FLEXIBLE POISSON PROCESS MODEL FOR TRIAL ACCRUAL
We propose a flexible Poisson process to model the observed pattern of patient accrual.
Consider a multi-institutional trial, the daily accrual of the coordinating center denotes by
{X(t), t = 1, 2, . . .}. Assume that the patient’s arrival follows a Poisson process and the
daily accrual rates are {λ(t), t = 1, 2, . . .}, where t indicates the accrual days.
Assume that accrual needs a period of time, say t0, to start and running up till reaching
full potential at a later time t1. Then the accrual becomes stable for a substantial period.
When the cumulative accrual is close to the target size N , say at time t2 > t1, the coor-
dinating center needs to assess the observed accrual pattern up to t2 and predict a future
date as the trial closure date in advance. It has also been widely observed that during the
final few days prior to the designated closure date, the accrual rate is much higher than the
past accrual rates. The following Poisson process model can be used for estimating the daily
accrual rate λ(t) :
λ(t) =

0, when t ≤ t0;
λ(t; β), when t0 < t ≤ t1;
µ, when t1 < t ≤ t3 −∆;
cµ, when t > t3 −∆
(3.1)
where t3 is the predicted closure date and ∆ is the length of the short period with high
accrual rate before t3. If the initiation of participating institutions follows a homogeneous
Poisson process before t1, then the intensity rate λ(t, β) during this period is a linear function
of t. In practice, time point t0 usually refers to the day before the first accrual; t1 can be
determined as the date when all of the participating sites have IRB approval and start
recruiting patients for the trial, or be speculated as a date when the trial looks like having
reached a stable accrual rate; t2 is always known. t2 is the time point when the coordinate
center needs to predict the future closure date. The constant c > 1 could be speculated
from accrual patterns of past trials that are similar to the current trial in terms of patient
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characteristics and treatment regimen. However, it is also possible that the historical clinical
trials are not available. Hence one way to evaluate the different values of c is to conduct
sensitivity analysis. The accrual rate during [t0, t1], λ(t, β) is usually unknown and often
assumed to be a linear function of t at the stage of trial design and planning.
Denote T , unknown and random, as the day when the accrual will surpass the target
sample size N . In the following context, we would consider the prediction of T with modeling
the accrual process as a nonhomogenous Poisson process as 3.1, the determination of t1 when
the accrual rates become constant, the model diagnostics on the assumptions of Poisson
process, and the extension to more complex models.
3.3 INFERENCE BASED ON PAST ACCRUAL PATTERN
Suppose after the accrual started, at time t2, where t2 > t1, we need to predict the future
accrual closure date. First, we need to estimate µ. We could use the following likelihood
based on the accrual from t0 to t2 to estimate µ. Consider the accrual pattern D(t) =
{X(t), t = 1, 2, . . . , t2} from t0 to t2 has been observed.
If the accrual rate during [t0, t1], λ(t, β), is a linear function of t, then the likelihood
function is:
L(µ) =
t2∏
t=1
p(X(t) = x(t);µ)
=
t2∏
t=t0+1
p(X(t) = x(t);µ, δ)
∝ {
t1∏
t=t0+1
exp(− t− t0
t1 − t0µ)(
t− t0
t1 − t0µ)
x(t)}{
t2∏
t=t1+1
exp(−µ)µx(t)}. (3.2)
The likelihood has two components. The first part contributes from when the accrual
increases linearly [t0 + 1, t1] and the second part contributes from the constant accrual rate
period, [t1 + 1, t2].
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Then, a log-likelihood function of L(µ) can be written in the form:
logL(µ) =
t1∑
t=t0+1
[− t− t0
t1 − t0µ+ x(t){log
t− t0
t1 − t0 + log µ}] +
t2∑
t=t1+1
{−µ+ x(t) log µ}
∝ −{
t1∑
t=t0+1
t− t0
t1 − t0 + (t2 − t1)}µ+
t2∑
t=t0+1
x(t) log µ
Therefore the maximal likelihood estimator (MLE) of µ is:
µ̂ =
∑t2
t=t0+1
x(t)∑t1
t=t0+1
t−t0
t1−t0 + (t2 − t1)
However, the assumption of a linear trend in accrual rates during the ramp-up period
[t0 + 1, t1] may not be appropriate. Then one may estimate µ based on the accrual data
during the period [t1 + 1, t2]. The corresponding likelihood function of µ becomes:
La(µ) ∝
t2∏
t=t1+1
exp(−µ)µx(t) (3.3)
logLa(µ) ∝
t2∑
t=t1+1
{−µ+ x(t) log µ} = −(t2 − t1)µ+
t2∑
t1+1
x(t) log µ.
The corresponding MLE of µ is
µ̂a =
∑t2
t=t1+1
x(t)
t2 − t1 .
Also, we can get the observed Fisher information of µ as:
Ia(µ) =
1
µ2
t2∑
t=t1+1
x(t)
Based on the Fisher information of µ, we can calculate the standard error of the ML estimator
µ̂a as
se(µ̂a) = Ia(µ̂a)
− 1
2 =
{∑t2t=t1+1 x(t)} 12
t2−t1 .
In practice, if the accrual rate stays stable after a certain time point, it would be simpler
to estimate the constant accrual rate λ(t) = µ according to the likelihood La(µ). However,
the choice of t1 would affect the estimate and a procedure for finding a sensible choice of t1
is important. How to select t1 will be discussed later.
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3.4 ESTIMATION OF c FROM A PAST TRIAL
As we observed from Figure 1, at the last few days before the designated closure date t3,
the participating sites usually try to get their patients in before the closure date because
they believe their patients would be benefited from the trial. Denote ∆ as the high accrual
period. The accrual rate usually runs up during the final few days, where t ∈ [t3−∆ + 1, t3].
In Function 3.1, the accrual rates during the last few days is donated as λ(t) = cµ, c > 1.
Based on the similar completed accrual data from a past multicenter trial carried out by the
same coordinating center, an estimate of c can be obtained from maximizing the following
likelihood function:
Lc(µ, c) =
t3−∆∏
t=t1+1
exp(−µ)µx(t)
t3∏
t=t3−∆+1
exp(−cµ)(cµ)x(t) (3.4)
logLc(µ, c) =
t3−∆∑
t=t1+1
[−µ+ x(t)logµ]− c∆µ+
t3∑
t=t3−∆+1
x(t)(logc+ logµ)
∝ −(t3 −∆− t1 + c∆)µ+
t3∑
t=t3−∆+1
x(t)logc+
t3∑
t1+1
x(t)logµ.
Then the MLE of c is:
ĉ =
(t3 −∆− t1)
∑T
t=t3−∆+1 x(t)
∆
∑t3−∆
t=t1+1
x(t)
.
For estimating c, the historical trial needs to share some similar characteristics as the cur-
rent running trial, such as disease status, treatment regimen, coordinate center, participants
institutions and etc. It may also involve clinical knowledge on patient accrual in practice.
However, it is always possible that such a similar completed clinical trial is not available.
We could conduct some sensitivity analysis to determine how the predicted accrual closure
date varies with potential choices of c. First, we could set c equal some potential values.
With a selected t1, we could project the corresponding closure dates and predicted total
final accruals by those closure dates. Based on the variation in closure dates and total final
accrual, the influence of c can be evaluated and then the value of c will be determined by
the primary investigators. The sensitivity analysis will be illustrated in Chapter 4.
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3.5 PROJECTION OF THE CLOSURE DATE
Suppose at time t2 > t1, about N(t2) patients have been randomized. We are interested in
predicting the future closure date after calculating the estimated MLE of the accrual rate
λ(t) = µ based on the observed accrual up to time t2. The coordinating center needs to set
a trial closure date T in order to notify participating sites of this closure date several weeks
in advance. Assume that T is the date when the accrual surpasses the target accrual N , i.e.,
T = min{t : N(t) ≥ N}. Two methods are proposed here to determine the future closure
date T . First, investigators are often interested in the expectation of T , E(T ), which is the
average of time when the overall accrual would pass the target sample size N . Another value
of interest is the quantiles of T , a future date Tα = min{t : pr[T ≤ t] ≥ 1 − α}. We could
pick a small α, say α = 0.1 or 0.05, so that at the closure date, we would be pretty sure that
the sufficient sample size would be achieved.
3.5.1 Estimation of E[T ]
The following algorithm is for calculating the expectation of the closure date, which is the
average of time when the overall accrual would pass the target sample size.
Let W = T − t2 denote as the additional accrual time after t2 to reach the target sample
size, then:
E[W ] =
∞∑
k=0
pr[W > k]
=
∞∑
k=0
pr[T − t2 > k] = pr[T − t2 > 0] +
∞∑
k=1
pr[T − t2 > k]
= 1 +
∞∑
k=1
pr[N(t2 + k) < N ]
= 1 +
∞∑
k=1
pr[N(t2 + k)−N(t2) < N −N(t2)]
= 1 +
∞∑
k=1
N−N(t2)−1∑
j=0
pr[N(t2 + k)−N(t2) = j]
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= 1 +
∞∑
k=1
N−N(t2)−1∑
j=0
e−µkµjk
j!
, (3.5)
where
µk = E[N(t2 + k)−N(t2)] =
 (k −∆)µ+ c∆µ, if k > ∆;ckµ, otherwise.
and ∆ is the high accrual period, a few days before the trial closure date. The estimated
expectation of T would be Ê(T ) = Ê(W ) + t2.
The probability of the closure date is greater than t2 or T − t2 > 0 is 1. It is because
that the total accrual N(t2) at t2, must be less than the target sample size, so we need to
accrue more patients and predict a closure date, which in turn means t2 is before the closure
date. Otherwise, if N(t2) = N , then t2 = T , it would be too late to inform the participating
centers to stop accruing since the whole process of close a trial could take several weeks.
We could also calculate the standard error of the estimated expectation of T , Ê[T ], using
Delta method. It equals the standard error of Ê(W ). We could calculate standard error of
Ê(W ) first. Denote θ = E[W ] = h(µ), a natural estimator of E[W ] is θ̂ = h(µ̂). Since
h(·) is a smooth function, the standard error of θ̂ can be estimated by the Delta method
as the multiple of the standard error of µ̂ and the absolute value of the derivation of θ̂,
s.e.(µ̂) | h′(µ̂) |. From the above representation of θ = h(µ), the functional form of h′(µ) is:
h′(µ) =
∞∑
k=1
[−e−µk dµk
dµ
+
N−N(t2)−1∑
j=1
{je−µkµj−1k − e−µkµjk}
dµk
dµ
/j!]
=
∞∑
k=1
dµk
dµ
[
N−N(t2)−2∑
j=0
e−µkµjk/j!−
N−N(t2)−1∑
j=0
e−µkµjk/j!]
= −
∞∑
k=1
dµk
dµ
e−µkµN−N(t2)−1k
(N −N(t2)− 1)!
= −
∆∑
k=1
cke−ckµ(ckµ)N−N(t2)−1
(N −N(t2)− 1)!
−
∞∑
k=∆+1
(k −∆ + c∆)e−µkµN−N(t2)−1k
(N −N(t2)− 1)! (3.6)
The standard error of T̂ or Ŵ can be calculated accordingly.
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3.5.2 Estimation of Tα
Given a small value of α, the quantile of future closure time Tα can be estimated using the
following algorithm. First, we calculate the CDF of T as a function of µ = µˆ. Then, we
could find out the smallest t to make Pr(T ≤ t)|µ=µˆ greater than or equal to 1−α. It could
be integrated as: we have (1−α)% confidence that the target sample size would be achieved
by the end of the day Tα.
For any given t > t2, let
1− α ≤ Pr(T ≤ t) = pr[N(t) ≥ N ]
= pr[N(t)−N(t2) ≥ N −N(t2)] = 1− pr[N(t)−N(t2) < N −N(t2)]
= 1−
N−N(t2)−1∑
k=0
pr[N(t)−N(t2) = k]. (3.7)
Note that, N(t) the total accrual at the end of the trial closure date can be derived as the
summation of patients accrued before t2 which is known, patients accrued after t2 + 1 but
before and during the high accrual period ∆.
N(t) = N(t2) +
t−∆∑
s=t2+1
x(s) +
t∑
s=t−∆+1
x(s)
and the additional accrual from time t2+1 to the closure time t follows a Poisson distribution
with the parameter as ((t−∆− t2)µ+ ∆cµ).
t−∆∑
s=t2+1
x(s) +
T∑
s=T−∆+1
x(s) ∼ P ((t−∆− t2)µ+ ∆cµ)). (3.8)
Therefore, the probability distribution function of the future accrual after t2 is
pr[N(t)−N(t2) = k] = pr[
t−∆∑
s=t2+1
x(s) +
T∑
s=t−∆+1
x(s) = k]
=
exp{−(t−∆− t2)µ− c∆µ}{(t−∆− t2)µ+ c∆µ}k
k!
,
where k = 0, 1, . . . , N − N(t2) − 1. Then substitute above function into Function 3.7, we
could calculate the smallest Tα, where Tα = min{t : pr[T ≤ t] ≥ 1− α} when µ is known.
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With µ estimated based on observed accrual data D(t2) up to t2, the estimator µ̂ can be
used in the above formula to estimate Tα but its variability needs to be taken into account.
A simple method for estimating the standard error of the estimator of Tα is the bootstrap
method. The algorithm is presented as following:
(1) For the dth bootstrap sample, randomly sample {N(t1 + 1), N(t1 + 2), . . . , N(t2)} with
replacement and denote the re-sampling accrual data as Y (d).
(2) For the dth bootstrap sample, obtain T
(d)
α . Repeat for d = 1, 2, ..., D, where D denotes
a large number.
(3) Let
¯̂
Tα =
1
D
∑D
i=1 T
(d)
α . Then, the standard error of the Tα is:
s.e.(T̂α) =
√
1
D−1
∑B
d=1 (T
(d)
α − ¯̂Tα)2.
The confidence interval of the estimator of Tα can be calculated accordingly.
3.6 PREDICTION OF TOTAL NUMBER OF ACCRUAL GIVEN A
CLOSURE DATE t3
After the closure date t3 is determined, either by Ê[T ] or T̂α, it would be also informative to
present the expected total accrual by t3. Because the future accrual N(t3)−N(t2) follows a
Poisson distribution.
N(t3)−N(t2) =
t3−∆∑
t=t2+1
x(t) +
t3∑
t=t3−∆+1
x(t) ∼ Poisson((t3 −∆− t2)µ+ c∆µ), (3.9)
A natural estimator of the final accrual size N(t3) can be calculated as the summation
of the number of patients accrued up to time t2, N(t2), and the estimated additional accrual
from t2 + 1 to the predicted closure date t3:
N̂(t3) = N(t2) + {(t3 −∆− t2) + c∆}µ̂,
The standard deviation of the estimated total accrual can be calculated based on the Poisson
distribution, S.D.(N̂(t3)) = [{(t3 −∆− t2) + c∆}µ̂] 12 .
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3.7 DETERMINATION OF t1
The estimation of the accrual rate λ(t) can be calculated based on two methods given the
likelihood functions 3.2 and 3.3. As we discussed in previous section, if the accrual rate
stays stable after a certain time point, it would be simpler to estimate the constant accrual
rate (t) = µ based on likelihood function 3.3. The estimation of the accrual rate or the
constant stabilized rate µ is critical because it affects the projection of the future closure
date. The precise estimation of accrual rate is contingent on the appropriate choice of t1,
when the accrual rate becomes stable, and an important assumption that patient accruals
during disjoint time intervals are independent. In this section we will focus on the appropriate
choice of t1 when the independence assumption stands.
There are different ways to determine t1, when the accrual rate becomes stable. One way
is based on model diagnosis after choosing t1 based on the observed accrual pattern up to
t2, such as residual analysis, Kolmogorov-Smirnov (K-S) test, and likelihood ration statistic
G2.
For a pre-determined t1, if the accrual rate is constant after t1, the residuals of t1 should
follow a standard normal distribution. The residuals can be calculated as:
(t) =
x(t)− µ̂a
µ̂
1
2
a
, t = t1 + 1, . . . , t2. (3.10)
Under a properly chose t1, the residuals should behave as N(0, 1). A plot of residual over
time or a Q-Q plot should reveal whether such a choice is appropriate see how close it is
from a the standard normal distribution.
A Kolmogorov-Smirnov test is also checking the distribution of residuals against the
standard normal distribution. The test statistic can be carried out as:
SKS = max{(t) : t1 + 1 ≤ t ≤ t2} (3.11)
with the null hypothesis that the sample is drawn from the reference distribution for the
one-side test. Here, the reference distribution is N(0, 1).
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Another approach is to use the likelihood-ratio statistic G2 to test the goodness of fit.
The test statistic is
G2 = 2
t2∑
t=t1+1
X(t) log
X(t)
µ̂
. (3.12)
which follows a Chi-square distribution with a degree of freedom (t2 − t1 − 1).
The largest p-values of the K-S test and G2 statistical tests lead to the optimal choice of
t1.
Since the accruals from t1 to t2 follow a homogeneous Poisson process, we could also
check the model assumption for the homogeneous Poisson process, which is the ratio of
sample variance to mean should be close to 1 for an appropriate choice of t1.
In practice, a possible range for t1 can be chosen based on the raw accrual pattern. Then
with t1 varying in this pre-determined range, the above statistical tests were carried out to
find out the optimal choice of t1 that leads to the largest p-values for those test statistics
and the ratio of sample variance to mean close to 1.
3.8 CORRELOGRAM FOR CHECKING SERIAL CORRELATION
After selecting an appropriate choice of t1, we need to test another important assumption
that patient accruals during disjoint time intervals are independent, which is also required for
the precise estimation of accrual rate. For equally spaced time series data, the correlogram
is a useful tool to detect whether there are serial correlations (Diggle, 1990 [8]). The daily
accrual could be considered as equally space data. For the daily accrual data from a large
multicenter trial, correlogram can be used to check whether there is serial correlation among
adjacent time intervals. For the sequence of daily accrual data {xt : t = 1, . . . , n}, we use x to
denote its sample mean, x = (
∑
xi)/n, and define the kth sample autocovariance coefficient,
gk =
n∑
t=k+1
(xt − x)(yt−k − y)/(n− k) (3.13)
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In the above formulae, the conventional use of the denominator is n instead. When n >> k,
as is the case here, there is no essential difference. Then, the kth sample autocorrelation
coefficient is
γk = gk/g0. (3.14)
A plot of γk against k is called the correlogram of the data {xi}. The plot of correlogram is
to check whether there is evidence of any serial dependence in the data series. The values of
γk greater than 2/
√
n in absolute value can be regarded as significant at about the 5% level.
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4.0 APPLICATION ON TWO CLINICAL TRIALS FROM THE NSABP
4.1 APPLICATION BASED ON NSABP TRIAL B-38
To illustrate the proposed method, we consider the accrual data of the motivating study, the
NSABP trial B-38, which was designed to compare the efficacy of three adjuvant chemother-
apy regimen for node-positive breast cancer patients. More information on this study was
introduced in Section 1.1. It was designed that a sample size 4,800 would achieve desired
power for the primary hypothesis. More than a hundred of sites participated in the process
of patient recruitment. The initiation date for each site was unknown. The first patient was
enrolled on November 3, 2004. By the end of March 20, 2007, 4465 patients were random-
ized. The Biostatistical Center was required to make a projection on the trial closure date.
Back then, a crude mechanism was considered in making the decision, which is the average
daily accrual during the 3-month period before March 20, 2007 and added 3 more days. It
was determined that the closure date was May 3, 2007. At the end of the designated closure
date, a total of 4894 patients were accrued into B-38. Total of 94 patients were over accrued.
Although several additional accruals might be necessary for this trial because dozens of pa-
tients withdrew consent or lost to follow-up later on. But accruing large number of additional
patients often leads to unnecessary cost and financial burden on the trial sponsors.
Therefore, our purpose is to project a more precise closure date and avoid the additional
accrued patients but make sure to accrue enough patients so that the study has sufficient
power to make meaningful inferences. At first, we will use the proposed method to estimate
the past accrual rate before March 20, 2007. Then, we will subsequently predict the closure
date and the estimated total accrual by the end of the closure date.
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4.1.1 Predication of closure date with t1 fixed
The main reason that we need hundreds of institutions or sites to participate in the patient
accrual is because there is a small chance for a single site to put a patient on the trial during a
short period, say a work day. We assume that the accrual from different sites is independent
among each other and the accrual during a certain time period is independent from another
disjoint time period. Therefore, the daily accrual rate follows a Poisson process. Based
on the observed accrual in Figure 1, at the beginning of the recruitment, the accrual rate
was relatively slow and non-linear. After several months, the accrual rates became stable.
However, during the final few days, the accrual rate is much higher than the past accrual
rates. Therefore, it is reasonable to use the Poisson process model defined by 3.1, to estimate
the accrual rate λ(t) = µ, where t indicates the accrual days. After excluding weekends and
holidays, if the first patient was accrued on November 3, 2004 (Wednesday) which is denoted
as day 1, and November 8, 2004 (Monday) would be day 4. Then, March 20, 2007 when the
coordinate data center made the prediction of closure date would be day 594 (t2 = 594).
With observed accrual up to March 20, 2007, we need to predict the future closure date
T when the total accrual would exceed the target sample size N = 4800. First, we need to
determine t1 when the accrual rate became stable. Based on the observed accrual in Figure
1, the accrual rate during about the first 4 months, from November 2004 to February 2005,
was not stable and non-linear. As a starting point, we could arbitrarily choose a date for t1
and assume that the accrual rate became stabilized on that day. Based on model diagnosis
tools, we could evaluate if the choice of t1 is appropriate. The methods of model diagnosis,
residuals analysis, Kolmogorov-Smirnov test, and likelihood ration statistic, were discussed
in Section 3.7.
For example, we could first choose t1 on March 7, 2005 (t1 = 83). Follow the method
in Section 3.3, the MLE of the constant daily accrual rate after March 7, 2005 is µ̂=8.13
and its standard error is se(µ̂)=0.126. However, the choice of t1 would affect the estimate of
daily accrual rate, which will be discussed in next section.
From the overall observed accrual data in B-38, as shown in Figure 1, the daily accrual
rate during the last 5 days was much higher than the daily accrual rate during the middle of
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the accrual period. This is because the participating institutions tried to enroll their patients
into this trial since they believe their patients would be benefited. In 3.1, the accrual rate
during that 5-day period is presented as cµ, where c is a constant. In practice, we would
have to estimate this information using accrual data from similar historical trials, in term of
disease status, treatment regimen, coordinate center, and participant institutions. However,
it is always possible that such a similar completed clinical trial is not available. In that case,
we could conduct some sensitivity analysis to help determining c. It will be discussed in later
section. Here, we calculated the MLE for c based on the overall accrual data from B-38, in
order to illustrate the method discussed in Section 3.4 on how to get MLE of c. cˆ = 2.24 is
estimated based on the overall accrual data from B-38 given t1=83 (7MAR2005).
Using the proposed method in Section 3.5, there are two methods to determine the future
closure date T . One is the average of time E(T ) when the overall accrual would pass the
target sample size N . Another one is the quantile of T, which is the probability of the total
accrual can pass the sample size N when tα = min{t : pr[T ≤ t] ≥ 1− α}. In the following
context, α was chosen as 0.05. In order to get the expectation of T, we need to first calculate
the estimated average of additional accrual days and its standard error, which are Ê(W )=26
and se(Ê(W ))=0.487, respectively. The projected total closure days Ê(T ) is calculated as
Ê(W )+ t2, where t2 = 594. The projected closure date Ê(T ) and the predicted total accrual
by the end of the estimated closure date E[N(t)]|
t=Ê(T )
are presented in Table 1.
The results of t̂α, its 95% CI and the estimated total number of final accrued patients
E[N(t)]|t=tˆα are also presented in Table 1. Based on the results in Table 1, it is more
conservative for predicting the closure date to use the quantiles of T . The results by this
method requires 3 additional accrual days, which allows more patients to be accrued. Its
95% confidence interval (CI) is estimated by the bootstrap method.
The accrual days, Ê(W ), Ê(T ) and t̂α were always rounded to their ceilings, that is, a
value of 21.2 would be rounded to 22. However, when we calculate the expected number of
total accrual by the closure date, E[N(t)]|
t=Ê(T )
or E[N(t)]|t=t̂α , the floor of the estimates
was used, i.e., 4821.8 would be reported as 4821.
In Appendix, Table 10 shows the actual date and accruals towards the end of the re-
cruitment. We can always compare our results with the real data. At the end of the day
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Table 1: Predicted closure date and estimated total final accrual at t1=7MAR2005 in B-38
Ê(T )(SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
620 (0.487) 4805 (18.5) 623 (622, 624) 4831 (19.1)
620, total of 4842 patients were actually enrolled. And, at the end of the day 623, total of
4872 patients were accrued. The actual total accruals were calculated as the observed total
accrual during the last five days prior to May 3, 2007, and the period between t2 + 1 and
t3 − 5. This is because that we have to always consider the possibility of high accrual at
the end of the recruitment. It has been observed in many large multi-center phase III trials.
It means that if the trial close on day 620, a high accrual period between days 616 to 620
will be expected. The results of the actual total accrual do not match the results from the
proposed method very well. It can be one of the indicator that the choice of t1 is not precise.
The results will be compared with other different choices of t1.
Given that t1=83 (7MAR2005) and cˆ = 2.24, the results in Table 1 can be interpreted as:
in average the overall accrual would surpass 4800 during day 620. In average, a total of 4805
patients would be accrued by the end of the day with a standard deviation of 18.5. We have
95% confidence that the overall accrual would surpass 4800 by the end of day 623. If day
623 is the designated closure date, in average a total of 4831 patients would be accrued with
a standard deviation of 19.1. We could also change the value of α in order to get different
quantiles of T .
The residuals resulted from fitting a homogeneous Poisson process on accrual data during
t1 and t2 are plotted in Figure 2. The Q-Q plot of the residuals of the estimated accrual
rate µ̂ is presented in Figure 3. It seems that the distribution residuals skewed a little to the
right, compared with a standard normal distribution. The results of Kolmogorow-Smirnov
test and likelihood-ratio statistics are SKS = 0.0992 (p value< 0.001) and G
2 = 635.11 with
df=510 (p value< 0.001), respectively. This suggests that accrual during March 7, 2005 and
March 20, 2007 did not follow a homogeneous Poisson process. We could observe that the
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most of the residuals during the first few days are below 0, and the values of SKS and G
2
need to be compared with the results based on different choices of t1. In next section, we
will explore the effects of t1 on the estimates of the accrual rate and the projection of the
closure date.
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Figure 2: Residuals of accrual rate over time at t1=07MAR2005 in B-38.
4.1.2 The choice of t1
The precise estimation of accrual rate is contingent on the appropriate choice of t1. The
method of choosing an appropriate t1 and the parameter estimates based on selected t1 will
be discussed here.
Based on the observed accrual from t0 to t2 in Figure 1, t1 was chosen on March 7, 2005
in above section. However, the Q-Q plot shows a majority of the residuals during the early
days are negative. It means the daily accrual rates are relatively lower at the first several
days after March 7, 2005 compare to later days. This suggests that t1 should be chosen
at a latter date. In this section, we propose a simple algorithm to help choose t1 within a
predetermined time period.
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Figure 3: Q-Q plot of the residuals of accrual rate at t1=07MAR2005 in B-38.
First, based on the overall observed accrual pattern from t0 to t2, we could determine a
potential time period from which t1 could be chosen. Second, we calculate the ratios of sample
variance to mean and p-values of G2 for each choice of t1 within the predetermined time
period. From t1 to t2, the accruals should follow a homogeneous Poisson process. Therefore,
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the ratio of sample variance to mean should be relatively close to 1 for an appropriate choice
of t1. When the p-value of G
2 is also relatively large, it indicates a precise choice of t1. Then,
we generate a figure, which includes both the information of the ratios and p-values given t1
varying in the predetermined time period. It helps to visualize the results and select t1.
Based on the accrual pattern from B-38 and the model fitting information from above
section given t1=7Mar2005, we decided that the potential time period for t1 to choose from
is March 30, 2005 to February 20, 2007 which was 20 days ahead of t2.
After calculating the ratios of sample variance to mean and p-values of G2 for various
choices of t1, we generated a Figure 4 including both the information of the ratios and p-
values given t1 varying in the predetermined time period. It shows in Figure 4 that the
ratio of sample variance to mean is relatively close to 1 and the p-value of G2 is relatively
large towards the end of 2006, ratio=1.01, p-value=0.429. So, the optimal choice of t1 was
December 29, 2006 for this trial.
Given t1=29DEC2006 and c = 2.24, µ̂ = 9.80, se(µ̂) = 0.426, the p-value for K-S test
is 0.536 and SKS = 0.1059. The predicted closure date and estimated total final accrual
are presented in Table 2. The plot of residuals over time and the Q-Q plot of residuals
are presented in Figure 5 and 6. Compare to the results of K-S test and the plots based
on t1=7MAR2005, the fit to the Poisson model was dramatically improved. However, the
standard error of µ̂ increased because that the number of observed data points decreased as
t1 was chosen closer to t2. Also, the absolute values of residuals are greater or equal than
3 in absolute value should be considered as outliers. There are not outliers observed from
Figure 5. If observed any, the outliers should be taken out and the accrual rate needs to be
re-estimated to compare with the original results, in order to determine the influence of the
outliers.
In Appendix, Table 10 shows the actual date and accruals towards the end of the recruit-
ment. Compare our results in Table 4 with the real data in Table 10, by the end of day 616,
in average 4809 patients were expected to enroll and 4802 patients were actually enrolled.
At the end of the day 618, in average 4829 patients were expected to enroll and 4819 patients
were actually accrued. The results of the actual total accrual match the results from the
proposed method pretty well. It indicates that the choice of t1=29DECf2005 is appropriate.
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Figure 4: The ratios of sample variance to mean and p-values of G2 for various choices of t1
in B-38.
4.1.3 When the constant c is unknown
After a closure date is predicted, most of the clinical trials usually experience a dramatic
increment in the daily accrual rate during the last few days before the closure date. It is
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Table 2: Predicted closure date and estimated total final accrual at t1=29DEC2006 in B-38
t1 Ê(T ) (SE) E[N(t)]|t=Ê(T ) (SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
29DEC2006 616 (2.657) 4809 (16.3) 618 (616, 621) 4829 (16.9)
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Figure 5: Residuals of accrual rate over time at t1=29DEC2006 in B-38.
because the participating sites try to put their patients on the trial before the deadline since
they believe that their patients would be benefited from the clinical trial. The accrual rate for
the last few days is estimated as λ(t) = cµ, as in 3.1. The constant c > 1 could be speculated
from the accrual patterns of past multi-center trials carried out by the same coordinating
center, which share some similarities, such as patient characteristics and treatment regimen.
This information is important to know since it affects the prediction of closure date and the
estimated total accrual.
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Figure 6: Q-Q plot of the residuals of accrual rate at t1=29DEC2006 in B-38.
However, it is possible the information of c is unavailable for some clinical trials if there
are no similar completed historical clinical trials available. In this section, we will conduct
sensitivity analysis to evaluate the influence of c when we set c at different values, and also
compare the results when c is fixed and the choice of t1 is varied. When c=1, we assume
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there is no increased accrual rate during the last few days before the closure date. When
c is increasing, the accrual rate increases at the last few days. Based on the overall B-38
accrual data, we know c is around 2.2. So, we will choose c at 1.5, 2, and 2.5 and compare
the results of predicted closure date and estimate total accrual.
In Table 4, t1 was chosen on December 29, 2006 based on the conclusion from the model
diagnosis in last section. In Table 3, t1 was chosen about 2 weeks before December 29, 2006,
which is December 14, 2006. The results from Tables 3 and 4 show that when c is smaller it
takes extra days to complete the accrual given any choice of t1. For example, when c=1.5 it
takes almost additional 5 days as comparing to c=2.5 for t1 on December 14 or 29 in 2006.
However, when we settle with a value of c, the predicted accrual days does not vary much,
about 1-2 days difference as t1 varies in about 2 weeks from December 14, 2006 to December
29, 2006. It requires additional 4-5 days if t1 was chosen on March 7, 2005, more than 1.5
years ago from December 29, 2006, see Table 1 and Table 2, when the value of c is the same.
After getting all of the results, we need to present the results to investigators or re-
searchers. It is important to show all of the results based on varied t1 and c, and then help in-
vestigators understand the results. For example, the results in Table 2 can be interpreted as:
given t1=540 (29DEC2006) and c = 2.2, the results of Ê(T ), (SE) and E[N(t)]|t=Ê(T ), (SD)
can be interpreted as: in average the overall accrual would take total 616 days with a standard
error of 2.66 and in average a total of 4809 patients could be accrued by the end of that day
with a standard deviation of 16.3. For the results of Tˆ0.05, (95%CI) and E[N(t)]|t=Tˆ0.05 , (SD),
it can be interpreted as: we have 95% confidence that the overall accrual would pass 4800
by the end of day 618. If day 618 is the designated closure day, in average there will be total
4829 patients accrued with a standard deviation of 19.1. In Appendix, Table 10, we can find
out that day 616 is April 19, 2007 and day 618 is April 23, 2007.
Also, it’s important to help them understand and select an appropriate c given the
sensitivity analysis. We could start with asking the following questions:
(1) After the closure date disseminated, would you expect the same accrual pattern as what
we observed in the past?
(2) If the accrual rate would increase during the final few days, how long is the window and
how much increment would be expected?
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Table 3: Predicted closure date and estimated total final accrual at t1=14DEC2006 for
varying c in B-38
c Ê(T ) (SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
1.5 620 (2.93) 4810 (16.3) 622 (620, 625) 4829 (16.9)
2 617 (2.93) 4806 (16.2) 620 (617, 622) 4834 (17.0)
2.5 615 (2.93) 4810 (16.3) 617 (615, 620) 4829 (16.9)
Based on the answer of the first question, we could decide if there are any potential
increased or maybe even decreased daily accrual rates at the end of the recruitment for some
cases. Then, we could decide what the value of c could be. If the investigator expects an
increment at the last a few days of the recruitment, we will consider c > 1. If the increment
is not expected, then c is most likely close to 1. If the investigator expects a very slow accrual
towards the end and thinks the patient enrollment can get sloppy at the end, we need to
remind them about the phenomenon we observed based on NSABP large multicenter phase
III cancer trials. If they think their trials are different than what we usually conducted at
NSABP and certain about a slow accrual at the end of the accrual, 0 < c < 1 need to be
considered. The second question would help us to decide the value of ∆, which is the number
of days at the end of the accrual with increased rates. Besides, it also asks that how much
of the increment would be expected. It will help us to decide if c is more towards 1 for a
small increment or 2 or 3 which associated with a larger increased rates. However, based on
what we observed from the trials from NSABP, we do not suggest a very large value of c,
no larger than 2.5 or 3. When c is less or equal than 2.5, it provides a more conservative
projection of the closure date. As we discussed previously, a large value of c could lead to
a shorter accrual period and less accrued patients than the target sample size. At the end,
after presenting the predicted accrual dates (Ê(T ) or t̂α) and the total predicted accruals to
the investigators under the various plausible choices of c, the investigators could make their
decision based on their confidence, the available resource and other considerations.
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Table 4: Predicted closure date and estimated total final accrual at t1=29DEC2006 for
varying c in B-38
c Ê(T )(SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
1.5 619 (2.66) 4814 (16.4) 621 (618, 623) 4833 (17.0)
2 616 (2.66) 4809 (16.3) 618 (616, 621) 4829 (16.9)
2.5 614 (2.66) 4814 (16.4) 616 (614, 618) 4933 (17.0)
4.1.4 Checking for Serial Correlation
Accrual data from multicenter trials can be treated as an equally spaced series. Correlogram
is helpful to check whether there is serial correlation among accruals during adjacent intervals
(Diggle, 1990). The kth sample autocovariance coefficient gk is calculated as in 3.13. The
kth sample autocorrelation coefficient γk is calculated as in 3.14. The overall correlogram
is a plot of γk against k. Here, we choose k=30, for 30 days starting from t1. The plot of
correlogram is to check if there is evidence of any serial dependence in the data series. The
values of γk greater than 2/
√
n in absolute value can be regarded as significant at about the
5% level, where n = t2−t1. At t1=29DEC2006 (days=540) and t2= 20MAR2007(days=594),
Figure 7 suggests none or very small serial correlation among this accrual data since there
is only one observation’s autocorrelation coefficient γk is a little bit over 0.27 on January 1,
2007 and majority of the γk’s are within the range of ±0.27. The 0.27 is calculated as 2/
√
n,
where n = 594− 541 = 54.
4.2 APPLICATION BASED ON TRIAL NSABP C-08
In NSABP trial C-08, a phase III, randomized clinical trial to compare disease-free survival of
patients with resected stage II or III adenocarcinoma of the colon treated with two adjuvant
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Figure 7: Overall correlogram for B-38, t1=29DEC2006.
39
chemotherapy regimen: luorouracil, leucovorin calcium, and oxaliplatin with versus without
bevacizumab. The pre-determined sample size was 2632. The trial was opened on September
15, 2004 and the first patient was accrued on October 14, 2004. On August 23, 2006 the
coordinating data center was required to project an accrual closure date for this trial based
on the observed accrual pattern and send it to participating sites several weeks in advance.
Based on the average daily accrual during the 3-month period before August 23, 2006 and
added 3 more days, October 6, 2006 was determined as the closure date. At the end of the
determined closure date, 2710 patients were accrued and randomized in this trial and a total
of additional 78 patients were accrued.
Figure 8 shows the daily accrual in trial C-08 over time, which illustrates the same
phenomenon as it observed in Figure 1 for trial B-38. During the first 3-4 months, the
accrual rate was increasing steadily and the accrual pattern became relatively stable after
March 2005. Again, it reflects the fact that it took time for the participating sites to meet
regulatory requirements and start recruiting patients for the trial. So, we choose t1 on March
10, 2005 (t1=100) as a starting point and assume the accrual rate became stabilized on that
day. t2 is August 23, 2006 (t2=467), which is the same as the actual data, when the accrual
pattern was observed by and the future closure date was determined on. The MLE of the
daily accrual rate is µ̂ = 5.89 and its standard error is se(µ̂) = 0.127.
From the overall observed accrual data in trial C-08, as shown in Figure 8, the daily
accrual rate during the last 5 days was much higher than the daily accrual rate before that
period. It increased about twice of the average daily accrual during the middle of the accrual
period. This is because the participating sites tried to enroll their patients into the trial since
they believed that the trial would benefit their patients. As it introduced in (3.1), the accrual
rate during the last 5-day is estimated as cµ. c could be speculated based on the accrual
pattern from a similar completed historical clinical trial, which was carried out by the same
coordinating center and has the same patient characteristics and treatment regimen as it
utilized in trial C-08. Here, cˆ = 1.8 was estimated using the overall accrual from October 14,
2004 to October 6, 2006 based on the accruals in C-08. It is just to illustrate the calculation
of c. When historical trials were not available, the sensitivity analysis of c will need to be
conducted and presented later.
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Figure 8: Overall daily accrual from NSABP trial C-08.
Given t1 = 100 (10MAR2005) and c = 1.8, the estimated average of additional accrual
days and its standard error are Ê(W ) = 22 and se(Ê(W )) = 4.23. The projected total
closure day is Ê(T ) = 489, which is t2 +E(W ). The predicted total accrual by the estimated
closure date is E[N(t)]|
t=Ê(T )
= 2639 with a standard deviation of 12.5, which could be
interpreted as at the end of the day 489 (25SEP2006) the overall accrual will surpass the
target sample size 2632 with a standard deviation of 12.5.
With α = 0.05, tˆα = 492 and it’s 95% CI is (491, 493). The projected total closure
days is E[N(t)]|t=t̂α = 2657 and its standard deviation is 13.1. Based on the results, we
could predict that we have 95% confidence that the overall accrual would surpass 2632 by
the end of the day 492 (28SEP2006). If day 492 is the determined closure date, in average a
total of 2657 patients would be accrued with a standard deviation 13.1. The results are also
summarized in Table 5.
The results of K-S test and Likelihood ratio statistics are SKS = 0.1066 (p-value< 0.001)
and G2 = 393.89 with df=366 (p-value=0.151), respectively. The residuals resulted from
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Table 5: Predicted closure date and estimated total final accrual at t1=10MAR2005 in C-08
t1 Ê(T ) (SE) E[N(t)]|t=Ê(T ) (SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
10MAR2005 488 (4.23) 2639 (12.5) 492 (491, 493) 2657 (13.1)
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Figure 9: Residuals of accrual rate over time at t1=10MAR2005 in C-08.
fitting a homogeneous Poisson process on accrual data during t1 to t2 are plotted in Figure
9. The Q-Q plot of the residuals of the estimated accrual rate µˆ is presented in Figure 10. It
seems that the distribution residuals skewed a little to the left, as comparing with a standard
normal distribution. We could observe some of the residuals during the first and last few
days are below 0 and potential outliers between October 2005 to May 2006 with relatively
large residuals which are greater than 3. It indicates that a better t1 needs to be determined
based on the observed accrual pattern.
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Figure 10: Q-Q plot of the residuals of accrual rate at t1=10MAR2005 in C-08.
We follow the same algorithm introduced in Section 4.1.2 to select an appropriate time
point for t1. First, need to decide on the time interval for selecting t1. Since the model
diagnoses given t1 on March 10, 2005 indicate t1 needs to be chosen at a later time, we choose
March 31, 2005 to July 26, 2006 as the predetermined time period from which to select t1.
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Then, we calculate the ratios of sample variance to mean and p-values of G2 given t1 varying
in the predetermined time period. Figure 11 displays both of the information, the ratios of
sample variance to mean and p-values of G2, given t1 varying within the predetermined time
period. On April 26 2006, the ratio of sample variance to mean is close to 1 and the p-value
of G2 is relatively large (ratio=0.898, p-value=0.591), which indicates an appropriate choice
of t1. Therefore, t1 is chosen on April 26, 2006 (t1=384).
We still choose c=1.8, so we can compare the results with t1 choosing at different date.
The estimated accrual rate µˆ is 5.99 and its standard error is 0.269. The projected total
closure days and the predicted final total accruals are presented in Table 6. Comparing to
t1 = 384 (26APR2006), the estimated accrual rate stays the same around 6 patients per day
but its standard error almost doubled and increases from 0.127 to 0.269. The increment
standard error is because when t1 = 384, the observed data points from t1 to t2 decreased.
Hence the information contributes to the likelihood function for estimating µ decreased. The
estimated total closure days and the predicted final total accruals do not varied much when
c is the same.
The goodness of fit criteria for estimating the accrual rate given t1 = 384 (26APR2006)
improved compare to t1 = 100 (10MAR2005). The results of K-S test and likehlihood-ratio
statistics are SKS = 0.2767 (p-value=0.277) and G
2 = 78.44 (p-value=0.591) with df=82.
The residual plot and Q-Q plot (Figure 12 and 13) are also improved.
After determining the date of t1, we need to conduct sensitivity analysis for varied values
of c. Also, the results will need to be evaluated for the same value of c but given different date
of t1. t1 was chosen on April 26, 2006 and April 13, 2006, about 10 days early from April 26,
2006, with c varying, Table 7 and 8 presented the results of the projected total closure days
and the predicted total accrual by the end of the closure date. The same conclusion can be
reached as in trial B-38. When c is smaller it takes extra days to complete the accrual, e.g.
when c=1 it takes almost additional 5 days as comparing to c=2. However, when we settle
with a value of c, the predicted accrual days does not vary much, about 1-2 days difference
as t1 varies about 10 days apart.
The plot of correlogram is to check if there is evidence of any serial dependence in the
data series. The correlogram for trial C-08, given t1 = 384 (26APR2006) is presented in
44
 0
. 0
0
. 2
0
. 4
0
. 6
0
. 8
1
. 0
1
. 2
      Sample Variance 
             Sample Mean 
 
          p-value of G2
26APR2006 
 (days: 115  150                 200     250          300        350            400                 450) 
 
   3/31/2005   5/19/2005     8/1/2005    10/12/2005    12/23/2005  3/9/2006     5/18/2006        7/26/2006  
Figure 11: The ratios of sample variance to mean and p-values of G2 for various choices of
t1 in C-08.
Figure 14. In the figure, we choose k=30, for 30 days starting from t1. The values of γk
greater than 2/
√
n = 0.22 in absolute value can be regarded as significant at about the 5%
level, where n = t2 − t1 = 467 − 384 = 83. There are two data points greater than 0.22. It
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Table 6: Predicted closure date and estimated total final accrual at t1=26APR2006 in C-08
t1 Ê(T ) (SE) E[N(t)]|t=Ê(T ) (SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
26APR2006 488 (4.10) 2640 (12.5) 491 (489, 494) 2652 (13.0)
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Figure 12: Residuals of accrual rate over time at t1=26APR2006 in C-08.
shows very small serial correlation among this accrual data.
In conclusion, the results of C-08 are consistent with what we found in B-38. After
selecting a time point t1, when the accrual rates become stable, we need to either find c
in a similar historical trial or conduct sensitivity analysis for varied c. Then, present the
predicted future closure date and estimated total accruals to the investigators. They could
make the decision based on their knowledge of the trial.
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Figure 13: Q-Q plot of the residuals of accrual rate at t1=26APR2006 in C-08.
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Table 7: Predicted closure date and estimated total final accrual at t1=13APR2006 for
varying c in C-08
c Ê(T ) (SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
1 492 (4.02) 2636 (12.3) 495 (493, 497) 2654 (13.0)
1.5 490 (4.02) 2639 (12.4) 493 (491, 495) 2657 (13.1)
2 487 (4.02) 2636 (12.3) 490 (488, 493) 2654 (13.0)
Table 8: Predicted closure date and estimated total final accrual at t1=26APR2006 for
varying c in C-08
c Ê(T )(SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
1 493 (4.10) 2640 (12.5) 495 (493, 498) 2652 (12.9)
1.5 490 (4.10) 2637 (12.4) 493 (491, 496) 2655 (13.1)
2 488 (4.10) 2640 (12.5) 490 (488, 493) 2652 (12.9)
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Figure 14: Overall correlogram for C-08, t1=26APR2006.
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5.0 CHANGE-POINT ANALYSIS
5.1 INTRODUCTION
As seen in previous chapters, the choice of the cut-off point t1, where the daily accrual rate
became stable and extended to current time t2, is critical to the estimation of average accrual
rate and determination of the trial closure date. Given t1, the sample mean should be close
to the sample variance for the accruals during [t1 + 1, t2] if the accruals during that period
are generated from a homogeneous Poisson process. Therefore whether the ratio between
the sample mean and the sample variance, for accruals during a period, is close to 1 or not
can be used to guide the choice of t1. Furthermore the goodness-of-fit test statistic G
2 is
also informative in finding appropriate t1. These tools were implemented in the previous
chapter. However, they are rather heuristic approaches. Here we are applying change point
analysis to find the cut-off t1 when the accrual rate would become stable and homogeneous
up to the current time t2.
Change point analysis is to find one or more locations where a parameter of a statistical
model changes its value. Such analyses have been applied in analysis of data collected from
the fields of finance, econometrics, software development, and medicine (Page, 1955 [14];
Chernoff and Zacks, 1964 [7]; Bhattacharyya and Johnson, 1968 [4]; Goldfeld and Quandt,
1973 [10]; Hinkley, 1970 [12]; Zhao and Wang, 2007 [17]). Akman and Raftery (1986) [2]
studied the change point problem in a continuous time Poisson process. Hinkley (1970) [12]
discussed the maximum likelihood method for estimating a change point in a sequence of
random variables, where the probability distribution changes, and the likelihood ratio test
statistic. Testing the existence of one or more change points in the means of a sequence inde-
pendent Poisson-distributed random variables was investigated by Henderson and Matthews
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(1993) [11] and the general approaches for change point problems were discussed in Bhat-
tacharya (1994) [5].
Regarding the daily accruals from a clinical trial as a sequence of Poisson-distributed
independent random variables, we will apply the maximum likelihood method to find the
change point where the means of these variables change.
5.2 LOCATING THE CHANGE POINT FOR A SEQUENCE OF
POISSON-DISTRIBUTED RANDOM VARIABLES
Consider a sequence of independent Poisson random variables {yk, k = 1, 2, . . . , n} with
means E[yk] = µk. If these yk’s are generated from a homogeneous Poisson process, then
µk’s are equivalent. However, if the corresponding Poisson process is non-homogeneous, µks
would change with k. Assume that µks only change once, that is, µ1 = µ2 = . . . = µτ 6=
µτ+1 = . . . = µn, where τ is the change point. The likelihood function is
L(µ1, µ2, τ) =
τ∏
i=1
f(yi;µ1)
n∏
i=τ+1
f(yi;µ2)
=
τ∏
i=1
e−µ1µyi1
yi!
n∏
i=τ+1
e−µ2µyi2
yi!
With τ fixed, the MLEs for (µ1, µ2) are (µ̂1τ , µ̂2τ ) = (
∑τ
i=1 yi/τ,
∑n
i=τ+1 yi/(n−τ)). Therefore
the logarithm of the profile likelihood of τ is
lpl(τ) ∝ {log(
τ∑
i=1
yi)− logτ}
τ∑
i=1
yi + {log(
n∑
i=τ+1
yi)− log(n− τ)}
n∑
i=τ+1
yi. (5.1)
The MLE of τ is τ̂ = arg max1≤τ≤n−1lpl(τ). One of the regularity conditions for the
maximum likelihood method for data with change point is that τ/n converges to a constant,
as n → ∞. Under the circumstance that the likelihood function lpl(τ) has multiple modes,
the MLE is often chosen as the mode that is not close to either the end of the period. The
derivation of a confidence set for τ̂ is very complicated (Bhattacharya, 1994) [5].
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5.3 TEST FOR A CHANGE POINT
For a given τ ∈ {1, 2, ..., n − 1}, it is of interest to test whether τ is truly a change point.
Two test statistics are often considered for this purpose. The first is the likelihood ratio test
for the following hypothesis test:
H0 : µ1 = µ2 = . . . = µn against HA : µ1 = µ2 = . . . = µτ 6= µτ+1 = . . . = µn.
Let
y¯ =
∑n
i=1 yi
n
, y¯r =
∑r
i=1 yi
r
, y¯′n−r =
∑n
i=r+1 yi
n
.
The likelihood ratio test for the hypothesis of no change (H0) against the alternative of
changing after τ is:
LRT = {
τ∏
i=1
e−y¯τ y¯yiτ
yi!
n∏
i=τ+1
e−y¯
′
n−τ y¯′yin−τ
yi!
}/
n∏
i=1
e−y¯y¯yi
yi!
(5.2)
= y¯τ y¯ττ y¯
′(n−τ)y¯′n−τ
n−τ /y¯
ny¯.
When n→∞, 2log(LRT ) follows the χ2 distribution under the null.
The other useful test statistic is the following:
T =
y¯τ − y¯′n−τ√
y¯τ/τ + y¯′n−τ/(n− τ)
. (5.3)
When n→∞, T is asymptotically N(0, 1) under the null.
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5.4 APPLY THE CHANGE-POINT ANALYSIS IN B-38 AND C-08
In the NSABP trial B-38, the pre-determined target sample size was 4800. Since the required
sample size is relatively large, patients were accrued from hundreds of institutions and sites
over time. During a work day, there is a small chance for a single institution to put a patient
on trial. Therefore, patient accrual during a certain time period is mostly independent
from the accrual during another disjoint time period and it approximately follows a Poisson
process. Denote the daily accrual over time k by yk and daily accrual rate by E[yk] =
µk, k = t0, t0 + 1, . . . , t2, where t2 is the time when we need to make the prediction of the
future closure date based on the observed accrual pattern from t0 up to t2.
In the proposed methods for predicting the final closure date, the accrual process during
[t1, t2] is assumed to be a homogeneous Poisson process and observed accrual daily counts yks
are a sequence of independent Poisson variables with a common mean. Then the observed
daily counts during [t1, t2] form the basis of prediction. Therefore an appropriate choice of
t1 is critical.
At the beginning of patient accrual, the daily accrual tended to be slow because many
participating institutions needed time to gear up their effort on patient accrual. The accrual
started getting stable after March of 2005. Our strategy is to find an initial date when the
daily accrual was stabilized, then find out whether there was a change point in daily accrual
rate with regarding the accrual counts, after that initial date and prior to t2, as a sequence
of independent Poisson random variables.
For the change-point analysis on B-38, we pick the starting point on July 15, 2005, based
on the accrual pattern from Figure 1. The potential change point τ will be between t175
(15July2005) and t593 (19Mar2007).
Figure 15 shows the logarithm of the profile likelihood of τ over time. On December
29, 2006, it has the largest value. The change-point analysis reaches the same result as the
algorithm we proposed in Section 4.1.2 based on the ratio between the sample mean and the
sample variance and the goodness-of-fit test statistic G2.
After identify τ , we could also test whether τ is truly a change point using the likelihood
ratio test 5.2 or the test statistic 5.3. The null hypothesis is H0 : µ1 = . . . = µn, against the
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Figure 15: The logarithm of the profile likelihood over time for NSABP trial B-38.
alternative hypothesis: Hα : µ1 = µ2 = . . . = µτ 6= µτ+1 = . . . = µn for some 1 ≤ τ ≤ n.
Given τ=540 (29Dec2006), the 2log(LRT)=13.66 with p-value< 0.001 and the other test
statistics T=-7.83 (p-value< 0.001). Therefore, τ̂=540 (29Dec2006) is a change point for
accruals from t175 (15July2005) to t593 (19Mar2007).
For NSABP trial C-08, the pre-determined target sample size was 2632. For the change-
point analysis on accrual data from C-08, we picked the starting point as May 19, 2005,
based on the accrual pattern from Figure 8. The potential change point τ will be somewhere
from t = 150 (19May2005) to t = 467 (23Aug2006).
Figure 16 shows the logarithm of the profile likelihood of τ over time. There are multiple
modes observed. The global mode was only a couple of days ahead of t2. We did not pick
t1 at that time. As stated earlier, this is required by the large sample property of MLE for
change point problems. We picked the first relatively large mode of the logarithm likelihood
is on May 26, 2006 (τ̂ = 406). The change-point analysis did not reach the same result as
the procedure which we proposed in Section 4.1.2 based on the ratio between the sample
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Figure 16: The logarithm of the profile likelihood over time for NSABP trial C-38.
mean and the sample variance, and the goodness-of-fit test statistic G2. This is probably
due to the volatile accrual of C-08 and one change point is not adequate for finding when
the accrual rate started being stabilized at the same rate at t2.
After identify τ , we could also test whether τ is truly a change point using the likelihood
ratio test 5.2 or the test statistic 5.3. The null hypothesis is H0 : µ1 = . . . = µn, against the
alternative hypothesis: Hα : µ1 = µ2 = . . . = µτ 6= µτ+1 = . . . = µn for some 1 ≤ τ ≤ n.
Given τ̂=406 (26May2006), 2log(LRT)=2.59 with p-value 0.068, and the other test statistics
T=4.83 (p-value< 0.001). At t406, the ratio of sample variance to mean is 1.06, which is
relatively close to 1. Moreover, the p-value of G2 for the given t1 is 0.288, which is not
significant and relatively large. Even though the LRT does not suggest that May 26, 2006,
is a real change point, these results still indicates that it is an appropriate choice of t1.
Also, given t1 is chosen on May 26, 2006, the predicted closure date and estimated total
final accrual, in Table 9, comparing to the results given t1 on April 26, 2006 (Table 8) are
very similar. For the projected closure date, it takes couple additional days for the sites to
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Table 9: Predicted closure date and estimated total final accrual at t1=26MAY2006 for
varying c in C-08
c Ê(T )(SE) E[N(t)]|
t=Ê(T )
(SD) Tˆ0.05 (95% CI) E[N(t)]|t=Tˆ0.05 (SD)
1 494 (4.70) 2635 (12.3) 497 (495, 501) 2652 (13.0)
1.5 492 (4.70) 2638 (12.4) 495 (492, 498) 2655 (13.1)
2 489 (4.70) 2635 (12.3) 492 (490, 496) 2652 (13.0)
accrue the required target sample size given the same value of c when t1 is chosen on May
26, 2006. However, the predicted total accruals are almost the same. It indicates when there
are multiple modes of the logarithm of the profile likelihood of τ over time and they are
relatively close to each other, it is safe to choose the earliest time point for t1 which ensure
the large sample property of MLE for change point problems.
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6.0 EXTENSION
6.1 INCORPORATE SITE INFORMATION OR COVARIATES
If for each participating site, the time when an IRB approval is obtained is available, the
Animisov and Fedorov (2007) [3] approach may be modified to get more precise estimate of
µ. However, the difference resulted in prediction of final closure date would be minimal if
there is any.
In usual multi-institutional clinical trials, not only daily accrual x(t)’s are available but
also some demographic factors Z such as age and other prognostic factors are also collected.
A more general Poisson process model is to incorporate such information into account by
modeling λ(t | z):
λ(t | z) = λ0(t) + β(t; z),
where care is needed for identifiability. Such models can be used to monitor the accrual rates
for various subsets of accrual population continuously. The results can be used as basis for
whether action should be taken to improve the accrual of specific subsets. It can provide a
better idea about the accrual pattern of sub-populations. Also, it can lead to more precise
estimate of closure date because more data are used.
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6.2 WHEN SERIAL CORRELATION EXISTS
When there are serial correlations among the accrual, a reasonable extension is to assume
that
X(t) ∼ Poisson(µ+ δ(t)),
where δ(t) is a Gaussian process with correlation:
corr(δ(t), δ(s)) = exp(−φ | t− s |).
However, the likelihood function of µ does not have an analytical form and numerical
integration is required. The prediction of future closure date would be very complicated,
because the joint distribution of the future daily accruals would be complex. Then a Bayesian
method would be more suitable for the purpose of predicting the future closure date.
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APPENDIX
THE CORRESPONDING ACTUAL ACCRUALS
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Table 10: Dates close to the trial closure and the corresponding actual accruals in B-38
Parameters Date Days Accumulative Accrual
t0 November 2nd, 2004 0 0
t2 March 20th, 2007 594 4465
Potential t3 April 18th, 2007 615 4793 *
April 19th, 2007 616 4802 *
April 20th, 2007 617 4811 *
April 23th, 2007 618 4819 *
April 24th, 2007 619 4832 *
April 25th, 2007 620 4842 *
April 26th, 2007 621 4849 *
April 27th, 2007 622 4860 *
April 30th, 2007 623 4872 *
May 1st, 2007 624 4881 *
May 2nd, 2007 625 4888 *
May 3rd, 2007 626 4894 *
* These accumulative accruals were calculated as the observed total accrual during the last
five days prior to May 3, 2007, and the period between t2 + 1 and t3 − 5.
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Table 11: Dates close to the trial closure and the corresponding actual accruals in C-08
Parameters Date Days Accumulative Accrual
t0 September 15th, 2004 0 0
t2 August 23th, 2006 467 2489
Potential t3 September 20th, 2006 486 2639 *
September 21st, 2006 487 2647 *
September 22nd, 2006 488 2653 *
September 25th, 2006 489 2664 *
September 26th, 2006 490 2669 *
September 27th, 2006 491 2677 *
September 28th, 2006 492 2681 *
September 29th, 2006 493 2684 *
October 2nd, 2006 494 2694 *
October 3rd, 2006 495 2697 *
October 4th, 2006 496 2700 *
October 5th, 2006 497 2707 *
October 6th, 2006 498 2710 *
* These accumulative accruals were calculated as the observed total accrual during the last
five days prior to October 6, 2007, and the period between t2 + 1 and t3 − 5.
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